Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Papulopustular Rosacea: full-pipeline trial registry
1 of 12 indexed Papulopustular Rosacea trials are currently recruiting.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 1 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Papulopustular Rosacea: 12 US clinical trials tracked, 1 recruiting.
Papulopustular Rosacea is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Journey Medical Corporation, running 2 of these trials.
Enrollment posture brief
Registry condition papulopustular-rosacea
OPEN 1 | RECR 8% | LATE 6 | EARLY 5 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Allergic Rhinitis (8% recruiting · 24 trials)
Papulopustular Rosacea lists 1 open slots (8% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Papulopustular Rosacea on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Papulopustular Rosacea is recruiting below its size-band peers.
1 of 12 indexed trials (8.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Papulopustular Rosacea research.
Journey Medical Corporation accounts for 2 of 12 trials (16.7%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Papulopustular Rosacea enrolment sits around 216 participants.
Median target enrolment is 216 among the 12 trials that report a genuine target (sentinel values excluded). 5 of those (41.7%) plan for fewer than 100 participants.
-
Papulopustular Rosacea research is mostly interventional.
12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
Narrows Institute for Biomedical Research
NCT06952517
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
bioRASI
NCT02393937
Phase 3 Papulopustular Rosacea Study
Galderma R&D
NCT01494467
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
Journey Medical Corporation
NCT05343455
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
Journey Medical Corporation
NCT05296629
A Twelve Week Safety and Efficacy Study in Rosacea
Maruho Co.
NCT01784133
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Alfasigma S.p.A.
NCT05150587
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
LEO Pharma
NCT00855595
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
Sol-Gel Technologies
NCT05675501
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
Galderma R&D
NCT01872715
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
Cutera
NCT02268474
An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
University of California, San Diego
NCT01933464
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Papulopustular Rosacea records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Papulopustular Rosacea trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Papulopustular Rosacea page
12 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Papulopustular Rosacea trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Journey Medical Corporation sponsors the most Papulopustular Rosacea trials on record, review their full trial history before evaluating a specific study. See Journey Medical Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Papulopustular Rosacea condition card totals 12 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.